Enterprise Value

2.103B

Cash

698.8M

Avg Qtr Burn

-32.8M

Short % of Float

14.81%

Insider Ownership

1.11%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Darovasertib (IDE196) (PKC Inhibitor) + crizotinib Details
Solid tumor/s, Metastatic uveal melanoma, Cancer

Phase 2/3

Data readout

IDE397 (MAT2A) Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma, Bladder cancer

Phase 2

Data readout

Darovasertib Details
Cancer, Solid tumor/s, Uveal melanoma

Phase 2

Data readout

Darovasertib Details
Cancer, Ocular melanoma

Phase 2

Update

Darovasertib (IDE196) (PKC Inhibitor) + crizotinib Details
Solid tumor/s, Metastatic uveal melanoma, Cancer, Cutaneous Melanoma

Phase 1/2

Data readout

Phase 1/2

Data readout

IDE397 (MAT2A) +/- AMG 193 Details
Cancer, Solid tumor/s, Non-small cell lung carcinoma

Phase 1/2

Data readout

IDE161 Details
Solid tumor/s, Cancer, ER+/HER2- breast cancer, Ovarian cancer, Endometrial cancer

Phase 1

Data readout

IDE397 (MAT2A) + Trodelvy Details
Solid tumor/s, Cancer, Bladder cancer

Phase 1

Initiation